Kehinde U.A. Adekola

Kehinde U.A. Adekola serves as an Associate Professor in the Department of Medicine (Hematology and Oncology) at Northwestern University's Feinberg School of Medicine. They maintain affiliations with multiple prestigious institutes including the Institute for Public Health and Medicine (IPHAM), Northwestern University Clinical and Translational Sciences Institute (NUCATS), Robert H. Lurie Comprehensive Cancer Center, and the Robert J. Havey, MD Institute for Global Health (IGH). Their clinical practice is based at Northwestern Memorial Hospital where they specialize in complex hematologic malignancies and transplantation cases.

Education and Training:

• MBBS: University of Lagos (2003)
• MS: Northwestern University (2013)
• Postdoctoral Fellow: The University of Texas Medical Branch at Galveston, Clinical Chemistry (2006)
• Resident: SUNY/State University of New York Downstate Medical Center, Internal Medicine (2009)
• Fellow: Northwestern University, McGaw Medical Center, Hematology-Oncology (2013)
• Fellow: University of Texas/MD Anderson Cancer Center, Stem Cell Transplant (2014)

Dr. Adekola's research program centers on stem cell/bone marrow transplantation for both malignant and non-malignant disorders, with particular emphasis on patient outcomes following these complex procedures. Their work significantly addresses cancer health disparities specifically within hematologic disorders, examining how socioeconomic, racial, and ethnic factors impact treatment access and survival outcomes. With a strong commitment to global health, they focus on improving outcomes for hematologic and oncologic conditions across diverse regions worldwide. Their research bridges clinical hematology/oncology with health services research, creating innovative approaches to address inequities in cancer care delivery.

Dr. Adekola's publication record demonstrates consistent contributions to advancing knowledge in hematopoietic stem cell transplantation, particularly regarding health disparities and outcomes research. Their work appears in high-impact journals including Blood and the Journal of the National Comprehensive Cancer Network, with recent publications (2024-2025) focusing on guidelines development for multiple myeloma and Waldenström Macroglobulinemia, as well as critical analyses of social determinants affecting access to transplantation for acute myeloid leukemia.

Scientific Recognition:

• Health Disparities Research Institute, National Institutes of Health (2020)

Dr. Adekola maintains significant leadership roles across major hematology and oncology organizations. They serve on the Data and Safety Monitoring Board for the Blood and Marrow Transplant Clinical Trials Network, the National Comprehensive Cancer Network, and multiple writing committees for the Center of International Blood and Marrow Transplant Research (CIBMTR), including the Acute Leukemia, Health Services and International Studies, Regimen-Related Toxicity and Supportive Care, and Late Effects and Quality of Life committees. They also serve as an Inspector for the Foundation for the Accreditation of Cellular Therapy.

Dr. Adekola leads three active clinical trials investigating chronic graft-versus-host disease (cGVHD), including the MA-GVHD-401 (THRIVE) observational study, a phase II trial investigating CYP-001 for acute GVHD, and a phase II study evaluating axatilimab in combination with ruxolitinib for newly diagnosed chronic GVHD. These trials reflect their commitment to advancing treatments for transplant complications while addressing health disparities in these patient populations.